BioXgen, a medical device company, today announced an open investment offering under Regulation Crowdfunding and a live investor webinar scheduled for April 30, 2026, at 10:30 a.m. Pacific Time. The event will feature a demonstration of the company's cardiac patch on a heart model, providing investors and the public with a firsthand look at the device's application and its potential to address a significant unmet medical need.
Each year, more than 500,000 Americans undergo open-heart surgery, and nearly half develop postoperative atrial fibrillation (POAF) within days. POAF is the most common complication of such procedures, yet no FDA-approved device is currently available to prevent it. BioXgen's cardiac patch is designed to be applied at the surgical site, with the company citing clinical data that shows a tenfold reduction in postoperative AFib rates.
The company reports that the device is fully developed and that its FDA pre-submission has been filed, marking a critical step toward regulatory review. During the webinar, Dr. David Skinner, President and CEO, and Dr. John Konhilas, Founder and CSO, will present the device on a heart model, explain its surgical application, discuss the clinical rationale, and answer live questions about the technology and investment opportunity.
“This is a chance for investors to see exactly what BioXgen has built and why we believe it could change the future of open-heart surgery,” said Dr. David Skinner. “We have moved beyond concept. The device is finished, the regulatory process is underway, and we are excited to open this next phase of growth to the community.”
The investment round is conducted under Regulation Crowdfunding, allowing eligible investors to participate as the company advances toward FDA clearance and commercialization. The webinar aims to provide a closer look at the device, the clinical problem of POAF, and the broader market opportunity. Attendees can see the product, learn about progress, and ask questions in a live interactive setting.
To learn more about the offering, visit invest.bioxgen.life. To attend the webinar, register here. BioXgen has filed a Form C with the Securities and Exchange Commission, available at https://invest.bioxgen.life/.
